해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 3.28.(목)

​

	보고서 (영문)
제약/바이오/ 임상시험	Janssen Gains Approval for Rybrevant as First-Line Treatment for NSCLC Subtype
	Innovent’s ROS1 TKI Is One Step Closer to Winning the Chinese NSCLC Market
	FLOW Trial Sheds Positive Light on Ozempic for CKD
	GLP1 Agonists to Surpass PD1 Antagonists as the Best Selling Drugs in 2024 and Beyond
	IO360: Phase II Trial Reveals Motixafortide's Efficacy in First-Line Pancreatic Cancer Treatment
	RNA-Based Drugs and the Impact of COVID-19
	Eli Lilly’s Partnership with Amazon to Boost Presence in Diabetes and Obesity Markets
	Padcev, Keytruda, and Balversa Leave Little Room for Opdivo in Urothelial Carcinoma
질환별	Polycystic Ovarian Syndrome: Competitive Landscape
	Cases of Tuberculosis Could Exceed Pre-Pandemic Numbers in England
	TB Potentially Transmissible in Undiagnosed Cases
	Cell & Gene Therapies in CNS Disorders
	Artificial Intelligence Identified Two Evolutionary Pathways of Prostate Cancer
	Female Vitiligo Patients Are at an Increased Risk of Osteoporosis
	Lung Cancer Deaths Have Declined Sharply in UK Middle-Aged Adults
컨퍼런스/ 심포지엄/ 학회/기타	AD/PD 2024: Early Diagnosis Remains a Hurdle for DMT in Parkinson’s
	AD/PD 2024: The Role of Blood-Based Biomarkers in Alzheimer’s Disease
	AD/PD 2024: Promise for TauRx’s HMTM, Despite Lacking Primary Endpoint Data
	AD/PD 2024: Cell Therapies Show Promise for Parkinson’s Disease Non-motor Symptoms
	AD/PD 2024: Eli Lilly’s Donanemab Hit with FDA Delay
	AD/PD 2024: Leqembi Data Supports Early Treatment Initiation for Better Outcomes
	AD/PD 2024: BioVie’s Novel NE3107 Shows Promise but Confirmatory Trial Needed
	AD/PD 2024: Exploring Cutting-Edge Therapies for Amyotrophic Lateral Sclerosis
	Defining the HTA Landscape for France and Germany: 2019–23
	Highlights from the IO360 Conference: PD-1 Inhibitors and Systemic Oncolytic Viral Immunotherapies
	New NIH Cancer Screening Research Network to Evaluate Screening Technologies
	BIOSECURE Act Could Impact WuXi-Manufactured Drugs for the US Market
	Clinical Trial Decline Highlights a Lack of Incentives for Drug Manufacturers